NASDAQ:NEOS - Neos Therapeutics Stock Price, Forecast & News

Neos Therapeutics trades on the NASDAQ under the ticker symbol "NEOS."

Neos Therapeutics Inc (NASDAQ:NEOS) posted its earnings results on Friday, November, 8th. The company reported ($0.04) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.11) by $0.07. The business earned $17.54 million during the quarter. Neos Therapeutics had a negative return on equity of 2,087.24% and a negative net margin of 35.77%. View Neos Therapeutics' Earnings History.

Neos Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Neos Therapeutics.

2 Wall Street analysts have issued 12 month price targets for Neos Therapeutics' shares. Their forecasts range from $3.00 to $10.00. On average, they anticipate Neos Therapeutics' share price to reach $6.50 in the next twelve months. This suggests a possible upside of 296.3% from the stock's current price. View Analyst Price Targets for Neos Therapeutics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neos Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neos Therapeutics.

News stories about NEOS stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Neos Therapeutics earned a media sentiment score of 1.6 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Neos Therapeutics.

Some companies that are related to Neos Therapeutics include Albireo Pharma (ALBO), AMAG Pharmaceuticals (AMAG), Osmotica Pharmaceuticals (OSMT), MannKind (MNKD), Aduro BioTech (ADRO), Syros Pharmaceuticals (SYRS), Evofem Biosciences (EVFM), Lexicon Pharmaceuticals (LXRX), Syndax Pharmaceuticals (SNDX), Bicycle Therapeutics (BCYC), Kamada (KMDA), Gemphire Therapeutics (GEMP), VBI Vaccines (VBIV), Seres Therapeutics (MCRB) and Avadel Pharmaceuticals (AVDL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Neos Therapeutics investors own include Exelixis (EXEL), Fibrocell Science (FCSC), Progenics Pharmaceuticals (PGNX), TG Therapeutics (TGTX), Verastem (VSTM), Synergy Pharmaceuticals (SGYP), SCYNEXIS (SCYX), Amicus Therapeutics (FOLD), T2 Biosystems (TTOO) and Agile Therapeutics (AGRX).

(NEOS) raised $60 million in an initial public offering on Thursday, July 23rd 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.

Neos Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Goldman Sachs Group Inc. (5.15%), Renaissance Technologies LLC (1.34%), Russell Investments Group Ltd. (1.17%), Boston Partners (0.46%), Jacobs Levy Equity Management Inc. (0.24%) and Hunter Associates Investment Management LLC (0.20%). Company insiders that own Neos Therapeutics stock include Alan L Heller, Gerald W Mclaughlin and Richard I Eisenstadt. View Institutional Ownership Trends for Neos Therapeutics.

NEOS stock was sold by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP, Algert Global LLC, State Street Corp and Alambic Investment Management L.P.. View Insider Buying and Selling for Neos Therapeutics.

NEOS stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Renaissance Technologies LLC, Boston Partners, Goldman Sachs Group Inc., Jacobs Levy Equity Management Inc., Hunter Associates Investment Management LLC, BCS Wealth Management and Virtu Financial LLC. Company insiders that have bought Neos Therapeutics stock in the last two years include Alan L Heller, Gerald W Mclaughlin and Richard I Eisenstadt. View Insider Buying and Selling for Neos Therapeutics.

Shares of NEOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NEOS stock can currently be purchased for approximately $1.64.

Neos Therapeutics has a market capitalization of $81.56 million and generates $49.99 million in revenue each year. The company earns $-51,670,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis. Neos Therapeutics employs 215 workers across the globe.View Additional Information About Neos Therapeutics.

The official website for Neos Therapeutics is http://www.neostx.com/.

Neos Therapeutics' mailing address is 2940 N. HIGHWAY 360, GRAND PRAIRIE TX, 75050. The company can be reached via phone at 972-408-1300 or via email at [email protected]